Top of this page
Skip navigation, go straight to the content
Vimpat®
Europe
In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Vimpat® solution for infusion may be used when oral administration is temporarily not feasible.
Prescribing information Europe
USA
In the US, Vimpat® (lacosamide) CV is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
As the safety of Vimpat® injection in pediatric patients has not been established, Vimpat® injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
Vimpat® injection may be used for adult patients when oral administration is temporarily not feasible.
In the U.S., Vimpat® is available as oral tablets, oral solution and injection.
Prescribing information USA
Related websites
Other countries
For availability of Vimpat® in other countries, please consult our local websites.